Gilead and Xilio have entered into an agreement under which Gilead received an exclusive global license to develop and commercialize Xilio’s XTX301, currently under P-I assessment
Under the collaboration, Xilio will obtain $43.5M upfront incl. $30M in cash & $13.5M in equity, additional $604M comprising of equity investments, a transition fee as well as specified development, regulatory & sales-based milestones plus high single digits to mid-teens global net-sales-based tiered royalties
Xilio will conduct XTX301’s P-I study and after the clinical data delivery, Gilead can take over its development for a $75M transition fee. Xilio will receive ~$29M in equity investments & milestones before transition
Ref: Gilead | Image: Gilead
Related News:- Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
